Recently, Shenzhen Raysightmed Co., Ltd. (abbreviated as "RaysightMed") announced the successful completion of a Series D financing round of nearly RMB 100 million. Supported by the coordinated efforts of municipal and district-level state-owned capital investment platforms in Guangzhou, the round was led by Guangzhou Health Industry Investment with Yuefu Fund participating as a follow-on investor, and has been successfully settled in Yuexiu District, Guangzhou.
It is reported that the financing proceeds will deepen the forward-looking strategic deployment of AI-driven vascular interventional surgical robots, develop an integrated “AI + Robotics” diagnostic and therapeutic platform, capture the future track of minimally invasive and precision interventions, and continuously establish dual competitive barriers in both technology and commercialization.
According to publicly available information, the three co-founders of RaysightMed possess distinguished backgrounds, each having accumulated over a decade of specialized expertise in their respective fields prior to founding the company.
RaysightMed's "Three Musketeers" —— from left to right: Ma Jun, Zheng Lingxiao, and Lan Hongzhi
Zheng Lingxiao, Founder and CEO of RaysightMed, earned his bachelor's degree from Beihang University and later pursued his Ph.D. at Johns Hopkins University, focusing on the application of physics-based simulation in the medical field. He previously led the 3D cardiac modeling project at Dassault Systèmes.
Lan Hongzhi, Co-founder and Chief Scientist of RaysightMed, holds bachelor's and master's degrees from Tsinghua University and a Ph.D. in Biomedical Engineering from Tulane University. After graduation, he served as a researcher at Stanford University's Cardiovascular Simulation Laboratory and has been continuously engaged in computational fluid dynamics research in the cardiovascular and cerebrovascular fields.
Ma Jun, Co-founder and Chief Technology Officer (CTO) of RaysightMed, was born in Linzhou, Henan Province, and received his bachelor's degree from the Department of Electrical Engineering at Tsinghua University.BiomedicalMajoring in [specialty], he/she later earned a Ph.D. in Biomedical Engineering from Johns Hopkins University, USA. He/She previously held positions at General Electric, Siemens Healthineers, and Intuitive Surgical, focusing on cutting-edge research in artificial intelligence algorithms, image-guided surgery, and other advanced technologies.
Zheng Lingxiao and Lan Hongzhi specialize in cardiovascular physical simulation, while Ma Jun excels in the integration of AI and surgical robots. Together, the three form a "golden combination" of "physical simulation + AI + robotics." In 2017, they founded "RaysightMed" in Shenzhen, a name that embodies their mission to safeguard cardiovascular and cerebrovascular health through intelligent products.
Since its inception, RaysightMed has primarily focused on the precision cardiovascular diagnosis and treatment sector. By integrating cutting-edge technologies such as artificial intelligence, hemodynamic simulation, and surgical robotics, the company has developed an integrated intelligent diagnostic and therapeutic platform covering clinical scenarios including coronary intervention, electrophysiology, and structural heart disease. Regarding core products, its flagship product, AngioQFA, serves as a globally leading integrated assessment platform for coronary physiology. By deeply integrating artificial intelligence and computational fluid dynamics (CFD) technology, the system completes simulation calculations in 10 seconds and generates a comprehensive procedural report within 3–5 minutes based on routine coronary angiography images. A single examination simultaneously obtains two core indices, FFR and IMR, achieving an efficient diagnostic and therapeutic model of "one scan, dual assessment." Currently, it has obtained the NMPA Class III Medical Device Registration Certificate and has been incorporated into the National Healthcare Security Administration's billing and reimbursement support system.
Following its market launch in June 2025, it has been deployed in dozens of hospitals in China. It is particularly suitable for the functional assessment of moderately stenotic lesions, enabling precise PCI decision-making and predicting postoperative outcomes. Its pioneering Bluetooth pressure sensor supports operation outside the catheterization laboratory, thereby reducing radiation exposure. Addressing the clinical unmet need for non-invasive, precise diagnostic tools, RaysightMed’s other benchmark product, Raysight Fraction (CT-FFR), leads the Chinese market in non-invasive coronary functional assessment. By integrating morphological and functional data, this platform evaluates vascular perfusion and plaque rupture risk, reduces rates of missed and misdiagnosis, minimizes unnecessary coronary angiography, and replaces invasive FFR pressure wire assessments. This saves manual quality control time and alleviates the burden on patients, clinicians, and the healthcare system. Meanwhile, the company’s newly introduced intracardiac echocardiography (ICE) focuses on precise intracavitary imaging diagnostics, further perfecting the end-to-end diagnostic and therapeutic workflow for electrophysiology and structural heart disease.
Furthermore, RaysightMed is actively expanding its strategic presence in AI-powered vascular interventional surgical robots. This financing round further underscores the company’s forward-looking investment in an AI-driven vascular interventional surgical robot ecosystem, aiming to secure a leading position in the emerging precision intervention sector. On the commercial front, RaysightMed has entered into a strategic partnership with Biosensors, a subsidiary of Blue Sail Medical, to drive regulatory approval, market access, and commercial distribution of the AngioQFA system in key markets across China and internationally. By leveraging Biosensors’ localized teams across the APAC and EMEIA regions, the collaboration aims to accelerate the global expansion of homegrown Chinese cardiovascular AI products.
According to available information, RaysightMed has completed six rounds of financing to date, securing substantial investments from a top-tier investor lineup including CAS Star Capital, Matrix Partners China, Green River Capital, Huachuang Capital, Tencent Investment, SDIC Capital, Guangzhou Financial Holdings Group, and Yuefu Fund.
In terms of market size, the global intravascular robotics market is projected to grow from USD 1.36 billion in 2025 to USD 4.04 billion by 2034. While the penetration rate of FFR (fractional flow reserve) functional assessment reaches 20%–30% in Europe and the United States and exceeds 50% in Japan and South Korea, it remains at a very low level in China and other emerging markets, indicating enormous growth potential. The successful closing of this Series D financing round serves as a strong endorsement by industry capital, reflecting high recognition of RaysightMed’s core technologies, industrial value, and commercialization progress.
